-
I-Mab NASDAQ:IMAB I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.
Location: | Website: www.i-mabbiopharma.com/en | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
17.49M
Cash
207.5M
Avg Qtr Burn
N/A
Short % of Float
0.45%
Insider Ownership
11.16%
Institutional Own.
31.87%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eftansomatropin alfa (TJ101) Details Pediatric growth hormone deficiency | BLA Submission | |
Lemzoparlimab combo w/ azacitidine Details High risk myelodysplastic syndromes | Phase 3 Data readout | |
Felzartamab (TJ202) (CD38 mAb) Details Multiple myeloma | Phase 3 Data readout | |
Efineptakin alfa (TJ107) (IL-7) Details Lymphopenia, Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Glioblastoma | Phase 2 Data readout | |
Uliledlimab (TJD5) (TJ004309) (anti-CD73)+ toripalimab Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Uliledlimab (TJD5) (TJ004309) (anti-CD73) +toripalimab Details Cancer, Ovarian cancer | Phase 2 Data readout | |
Uliledlimab (TJD5) (TJ004309) (anti-CD73)+ toripalimab Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Felzartamab Details Primary Membranous Nephropathy | Phase 1/2 Update | |
MOR210 (TJ210) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Givastomig (TJ-CD4B/ABL111) Details Solid tumor/s | Phase 1 Data readout | |
Ragistomig (TJ-L14B/ABL503)(PD-L1 x 4-1BB bispecific antibody) Details Solid tumor/s, Cancer | Phase 1 Update | |
Enoblituzumab (TJ271) + Pembrolizumab Details Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s | Failed Discontinued | |
Felzartamab (MOR202) (CD38) Details IgA nephropathy | Failed Discontinued | |
Olamkicept (TJ301) (gp130 IL-6 inhibitor) Details Ulcerative colitis, Autoimmune disease | Failed Discontinued |